Patients with type 2 diabetes and moderate renal impairment who took oral semaglutide in a phase 3a trial reported a larger reduction in glycated hemoglobin and more weight loss than patients taking placebo.
Novo Nordisk today announced that topline results for its phase 3a trial of oral semaglutide show the drug reduced glycated hemoglobin (A1C) and helped patients with type 2 diabetes (T2D) lose weight after 26 weeks. If successful, the drug would be the first glucagon-like peptide-1 (GLP-1) taken once daily as a tablet.
PIONEER 5 is 1 of 10 trials involving the study drug. An injectable form of semaglutide, sold as Ozempic, received FDA approval last year.
Results of the PIONEER 5 trial, which involved 324 people with T2D and moderate renal impairment, showed that those treated with 14 mg oral semaglutide saw an A1C reduction of 1.1%, compared with 0.1% for placebo. The group taking the study drug lost 3.7 kg compared with 1.1 kg with placebo.
From an average baseline A1C of 8.0%, the share of people reaching the target A1C of 7.0% by week 26 was greater with oral semaglutide than with placebo: 64%, compared with 21%. A target of 7.0% is recommended by the American Diabetes Association and other major diabetes professional organizations, as well as the Joslin Diabetes Center.
An earlier trial in the PIONEER program tested oral semaglutide at different doses.
According to the statement from Novo Nordisk, PIONEER 5 involved 2 statistical approaches:
The population in PIONEER 5 had T2D and moderate renal impairment inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.
“The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk.
“Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options,” he said. “If approved, oral semaglutide represents an efficacious new solution.”
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen